Key result
A combination of insulin, heparin, atorvastatin, and omega-3-acid ethyl esters reduced triglyceride levels from 4,435 mg/dL to 880 mg/dL after 9 days in a non-diabetic patient with pancreatitis.
Why the study?
The efficacy of therapies for hypertriglyceridemia-induced pancreatitis may vary based on etiology, and standardized approaches remain needed, particularly regarding the appropriateness and dosing of insulin therapy in patients without diabetes.
Does a combination of insulin, heparin, atorvastatin, and omega-3-acid ethyl esters reduce triglyceride levels in a non-diabetic patient with hypertriglyceridemia-induced pancreatitis?
Case Report (n=1)
Does a combination of insulin, heparin, atorvastatin, and omega-3-acid ethyl esters reduce triglyceride levels in a non-diabetic patient with hypertriglyceridemia-induced pancreatitis?
A combination of insulin, heparin, atorvastatin, and omega-3-acid ethyl esters successfully reduced extreme hypertriglyceridemia in a non-diabetic patient with acute pancreatitis.
No takes yet. Share an insight, caveat, or question.
May support adjunctive use in refractory hypertriglyceridemic pancreatitis; hypothesis-generating and requires prospective validation.
Cortes et al. (2022) conducted a case report in Hypertriglyceridemia-Induced Pancreatitis (n=1). Insulin, heparin, atorvastatin, and omega-3-acid ethyl esters was evaluated on Triglyceride (TG) level. A combination of insulin, heparin, atorvastatin, and omega-3-acid ethyl esters reduced triglyceride levels from 4,435 mg/dL to 880 mg/dL after 9 days in a non-diabetic patient with pancreatitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: